On November 1, 2024 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, reported its participation in upcoming investor conferences (Press release, Black Diamond Therapeutics, NOV 1, 2024, View Source [SID1234647633]). Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel Healthcare Conference fireside chat at 4:10pm ET on Tuesday, November 19, 2024
Piper Sandler 36th Annual Healthcare Conference fireside chat at 3:00pm ET on Wednesday, December 4, 2024

Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.